HCM N logo

HUTCHMED (China) BMV:HCM N Stock Report

Last Price

Mex$819.63

Market Cap

Mex$34.8b

7D

0%

1Y

0%

Updated

13 Jun, 2023

Data

Company Financials +

HUTCHMED (China) Limited

BMV:HCM N Stock Report

Market Cap: Mex$34.8b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HCM N Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details

HCM N fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£819.63
52 Week HighUK£0
52 Week LowUK£0
Beta0.88
1 Month Change0%
3 Month Change0%
1 Year Change0%
3 Year Changen/a
5 Year Changen/a
Change since IPO-2.89%

Recent News & Updates

Recent updates

Shareholder Returns

HCM NMX PharmaceuticalsMX Market
7D0%0.7%-0.6%
1Y0%-22.3%-9.7%

Return vs Industry: HCM N exceeded the MX Pharmaceuticals industry which returned -15% over the past year.

Return vs Market: HCM N underperformed the MX Market which returned 3.7% over the past year.

Price Volatility

Is HCM N's price volatile compared to industry and market?
HCM N volatility
HCM N Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.1%
10% most volatile stocks in MX Market7.1%
10% least volatile stocks in MX Market2.8%

Stable Share Price: HCM N has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HCM N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,280Wei-Guo Suwww.hutch-med.com

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3’-kinase delta).

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
HCM N fundamental statistics
Market capMex$34.76b
Earnings (TTM)-Mex$6.23b
Revenue (TTM)Mex$7.37b

4.7x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HCM N income statement (TTM)
RevenueUS$426.41m
Cost of RevenueUS$698.00m
Gross Profit-US$271.59m
Other ExpensesUS$89.25m
Earnings-US$360.83m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.43
Gross Margin-63.69%
Net Profit Margin-84.62%
Debt/Equity Ratio2.8%

How did HCM N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/13 21:39
End of Day Share Price 2023/03/16 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish